Elsevier

The Lancet

Volume 338, Issue 8778, 23 November 1991, Pages 1315-1318
The Lancet

HYPOTHESIS
Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia

https://doi.org/10.1016/0140-6736(91)92604-ZGet rights and content

Abstract

Maintenance chemotherapy with 6-mercaptopurine and methotrexate, widely believed an essential contribution to the high cure rates achieved in children with acute lymphoblastic leukaemia (ALL), is thought to work by killing the leukaemia cells that remain after intensive chemotherapy. We suggest instead that ALL commonly arises in precursor B cells normally programmed to die, and that maintenance chemotherapy does not kill these cells but controls growth of the leukaemia clone so that programmed death can occur. A similar approach may apply to other cancers in which programmed death is intrinsic to the normal counterparts of the neoplastic cells.

References (37)

  • Rb Gallagher et al.

    To B or not to B: that is the question

    Immunol Today

    (1991)
  • B. Barlogie et al.

    Plasma cell myeloma: new biological insight and advances in therapy

    Blood

    (1989)
  • La Clavell et al.

    Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia

    N Engl J Med

    (1986)
  • H. Riehm et al.

    Therapy results of five ALL-BFM studies since 1970. Implications of risk factors for prognosis

    Curr Stud Hematol Blood Transfus

    (1987)
  • D. Pinkel

    Curing children of leukemia

    Cancer

    (1987)
  • Jh Goldie et al.

    The genetic origin of drug resistance in neoplasm: implications for systemic therapy

    Cancer Res

    (1984)
  • D. Pinkel et al.

    Drug dosage and remission duration in childhood lymphocytic leukemia

    Cancer

    (1971)
  • Cited by (50)

    View all citing articles on Scopus
    View full text